GlassScriptPhysician profile
Amanda J Adams
NPI 1457347064
$13,727.19
in general payments reported to CMS, 2019-2025
45 companies · $1,951 in 2025
The $1,951 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,064 · 2020: $1,360 · 2021: $1,867 · 2022: $1,584 · 2023: $2,363 · 2024: $2,538 · 2025: $1,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,852.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,106.48 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $1,721.14 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,588.84 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,253.21 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $1,112.79 | 2019-2025 | Repatha, Evenity, Repatha |
| Lilly USA, LLC | $909.33 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $825.90 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $727.47 | 2019-2025 | Trintellix, Glassia |
| Allergan, INC. | $461.60 | 2019-2020 | |
| Pfizer INC. | $396.48 | 2019-2025 | |
| Axsome Therapeutics, INC. | $344.71 | 2023-2025 | Auvelity, Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.71 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $188.97 | 2019-2021 | |
| Exact Sciences Corporation | $181.52 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $173.19 | 2019-2023 | Belsomra |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.